In an end-of-year IPO blitz, 4 biotechs pitch new offerings totaling $370M
An immuno-oncology company focused on a more potent T cell attack. Two biotechs that grabbed assets off the remaindered shelves at Big Pharma. And one …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
